Compare Ascendis Pharma A/S (ASND) vs Nerdwallet Inc (NRDS) Price & Performance

Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.

The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.

NRDS trades at $9.47, down 1.56% today, with a bullish technical signal from moving averages and strong fundamentals including a 93% gross margin and three consecutive earnings beats. Revenue grew to $837M in 2025, with net income reaching $49M. Analyst consensus is Buy with a $12.75 target, implying 35% upside. Positive news highlights the company's pivot to higher-margin transactions and launch of a Financial Resilience Index.

The outlook is positive given undervaluation (P/E 10.18, P/S 0.83) and earnings momentum, but risks include search traffic dependence and projected negative cash flow in 2026. Institutional sentiment is bullish with 66% Buy ratings, supporting a constructive view for long-term investors seeking growth at a reasonable price.